Association of busulfan area under the curve with veno-occlusive disease following BMT

Bone Marrow Transplantation

Volumn 17, Issue 2, 1996, Pages 225-230

  Dix, S P ^a   Wingard, J R ^b   Mullins, R E ^b   Jerkunica, I ^b   Davidson, T G ^a   Gilmore, C E ^a   York, R C ^a   Lin, L S ^c   Devine, S M ^b   Geller, R B ^b   Heffner, L T ^b   Hillyer, C D ^b   Holland, H K ^b   Winton, E F ^b   Saral, R ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Busulfan; Pharmacokinetics; Veno occlusive disease

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; BUSULFAN; CIRCADIAN RHYTHM; CYCLOPHOSPHAMIDE; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK;

EID: 13344259305     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jones RJ, Lee KSK, Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1988; 44: 778-783.
2. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors. Hepatology 1984; 116: 116-122.
3. McDonald GB, Sharma P, Matthews DE et al. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985; 36: 603-638.
4. Rollins BJ, Hepatic veno-occlusive disease: AM J Med 1986; 81: 297-306.
5. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort of 355 patients. Ann Intern Med 1993; 118: 255-267.
6. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20 (suppl. 4): 18-25.
7. Santos GW, Tutschska PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. New Engl J Med 1983; 309: 1347-1353.
8. Peters WP, Henner WD, Grochow LB et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous marrow support in the treatment of solid tumors. Cancer Res 1987; 47: 6402-6406.
9. Grochow LB, Jones RJ. Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
10. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475-2479.
11. Yeager AM, Wagner JE, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.
12. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994; 84: 2357-2362.
13. Miller DR. Determining ideal body weight (and mass). Am J Hosp Pharm 1983; 40: 1622 (letter).
14. Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker: New York, 1982, pp 445-449.
15. Fisher RA. The Design of Experiments, (8th edn). Oliver and Boyd: Edinburgh, 1966.
16. Fleiss JL. Statistical Methods for Rates and Proportions, (2nd edn). J Wiley: New York. 1981.
17. Schuler U, Schroer S, Kuhnle A et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759-765.
18. Chen TL, Grochow LB, Hurowitz LA et al. Determination of busulfan in human plasma by gas chromatography with electron capture detection. J Chromatogr 1988; 425: 303-309.
19. Hassan M, Oberg G, Ehrsson H et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
20. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of hish-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-134.
21. Hasssan M, Oberg G, Bjorkholm M et al. Influence of prophylactic anticonvulsant therapy on high-dose busulfan kinetics. Cancer Chemother Pharmacol 1993; 33: 181-186.